Variables | Salbutamol group (n = 209) | Fluticasone/Salmeterol group (n = 206) | 1P-value | ||||||
---|---|---|---|---|---|---|---|---|---|
Normal | overweight | Obese | P-value | Normal | overweight | obese | P-value | ||
Number of participants (%) | 70 (33.49) | 69 (33.01) | 70 (33.49) | 68 (33.01) | 68 (33.01) | 70 (33.98) | |||
Age (years) | 37.93 ± 12.4 | 38.49 ± 14.5 | 42.95 ± 13.8 | 0.059 | 39.14 ± 8.1 | 41.85 ± 9.3 | 45.14 ± 11.9 | 0.036 | NS |
Gender (M/F) | 46/24 | 33/36 | 26/44 | 0.094 | 33/35 | 38/30 | 31/39 | 0.174 | NS |
BMI (kg/m2) | 22.96 ± 2.21 | 27.81 ± 1.37 | 35.67 ± 4.58 | < 0.001* | 23.2 ± 5.83 | 28.06 ± 1.8 | 35.2 ± 6.3 | < 0.001* | NS |
FEV1 (L) | 3.15 ± 1.2 | 2.93 ± 0.81 | 2.79 ± 1.03 | 0.115 | 3.72 ± 1.46 | 3.29 ± 1.28 | 3.24 ± 1.17 | 0.064 | NS |
FEV1% of predicted | 76.2 ± 12.6 | 74.5 ± 16.4 | 72.41 ± 18.3 | 0.372 | 78.28 ± 12.5 | 77.05 ± 11.3 | 76.56 ± 12.9 | 0.699 | NS |
FVC (L) | 3.45 ± 1.14 | 3.41 ± 0.78 | 3.34 ± 0.97 | 0.796 | 4.16 ± 1.41 | 3.92 ± 1.36 | 3.64 ± 1.27 | 0.079 | NS |
FVC% of predicted | 89.78 ± 10.8 | 87.15 ± 12.37 | 86.63 ± 14.52 | 0.281 | 90.18 ± 12.8 | 87.22 ± 10.41 | 85.34 ± 13.62 | 0.068 | NS |
FEV1/FVC | 73.88 ± 17.61 | 73.15 ± 19.28 | 70.94 ± 18.13 | 0.615 | 76.83 ± 15.8 | 74.52 ± 14.7 | 71.24 ± 16.51 | 0.112 | NS |